1 / 8

Risk of Developing Alzheimer’s Disease in Persons with MCI

Risk of Developing Alzheimer’s Disease in Persons with MCI. Survival curve of persons characterized as having a mild cognitive impairment for 6 years. Approximately 80% have converted to dementia during this time. Peterson RC, et al., Arch Neurol . 58:1985-1992, 2001.

anana
Download Presentation

Risk of Developing Alzheimer’s Disease in Persons with MCI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years. Approximately 80% have converted to dementia during this time. Peterson RC, et al., Arch Neurol. 58:1985-1992, 2001.

  2. Volume of Hippocampus and Rate of Shrinkage Predicts Crossover from MCI to AD Normal, 75 years old Alzheimer’s disease, 75 years old De Leon MJ, 1999 Jack CR, et al, Neurology 55: 484-489, 2000

  3. PET Imaging of Amyloid Deposits in Alzheimer’s Disease vs Normal Controls PET imaging with a novel tracer, Pittsburgh Compound-B (PIB), can provide quantitative information on amyloid deposits in living subjects. Source: Klunk, et al. Ann Neurol 2004: 55:306-319.

  4. Current Drug Treatments for AD • Acetylcholinesterase inhibitors for mild to moderate AD • Tacrine (Cognex) • Denepezil (Aricept) • Rivastigmine (Exelon) • Galantamine (Reminyl) • Neuroprotective agent for moderate to severe AD • Memantine (Namenda)

  5. Funded AD Prevention and Selected Treatment Trials April 2002

  6. Complementary & Alternative Therapies for AD • Ginkgo Evaluation of Memory (GEM) study • Clinical trial of huperzine • Traditional Asian medicines • High intensity light therapy

  7. REACH II Intervention The REACH II intervention is a multi-component intervention designed to address five areas linked to caregiver risk profile: • Safety • Social Support • CR Problem Behaviors • Emotional well-being • Self-care and Health Behaviors

More Related